LFA
JAZZ icon

Legacy Financial Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Legacy Financial Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-383
Closed -$55K – 515
2019
Q1 		$55K Sell
383
-70
-15% -$9.13K 0.02% 262
2018
Q4 		$56K Buy
+453
New +$67.2K 0.02% 224

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Legacy Financial Advisors's JAZZ Position: Q2 2019 in Review

Legacy Financial Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2019, closing a stake of 383 shares — an estimated $55K sold.

Legacy Financial Advisors first reported a position in JAZZ in Q4 2018 and held it in 2 quarters. The position peaked at $56K in Q4 2018. 416 funds tracked by Wall St. Rank hold JAZZ as of Q2 2019.

  • Legacy Financial Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Legacy Financial Advisors sold 383 Jazz Pharmaceuticals shares in Q2 2019, an estimated $55K.
  • Legacy Financial Advisors first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Legacy Financial Advisors's Jazz Pharmaceuticals position peaked at $56K in Q4 2018.
  • 416 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2019.

Based on Legacy Financial Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.